Appetite suppressants and valvular heart disease

Current Opinion in Cardiology

Volumn 17, Issue 5, 2002, Pages 486-492

  Seghatol, Frank F ^a   Rigolin, Vera H ^a  

^a Northwestern Medical Faculty Foundation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANOREXIGENIC AGENT; DEXFENFLURAMINE; FENFLURAMINE; PHENTERMINE;

AORTA VALVE REGURGITATION; DIET RESTRICTION; DRUG SAFETY; ECHOCARDIOGRAPHY; HUMAN; MITRAL VALVE REGURGITATION; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; RISK ASSESSMENT; VALVULAR HEART DISEASE; WEIGHT REDUCTION;

APPETITE DEPRESSANTS; CARCINOID HEART DISEASE; DEXFENFLURAMINE; FENFLURAMINE; HEART VALVE DISEASES; HUMANS; HYPERTENSION, PULMONARY; PHENTERMINE;

EID: 0036752294     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001573-200209000-00007     Document Type: Review

References (31)

1. Kuczmarski RJ, Flegal KM, Campbell SM, et al.: Increasing prevalence of overweight among US adults. The National Health and Nutrition Examination Surveys, 1960 to 1991. JAMA 1994, 272:205-211.
2. National Task Force on the Prevention and Treatment of Obesity. Overweight, obesity, and health risk. Arch Intern Med 2000, 160:898-904.
3. Yanovski SZ, Yanovski JA. Obesity. N Engl J Med 2002, 346:591-602. This article is a comprehensive review of the pathophysiology and available treatment of obesity.
4. Connolly HM, McGoon MD. Obesity drugs and the heart. Curr Probl Cardiol 1999, 751-792. This article is an excellent review of appetite suppressants and valvular disease and pulmonary hypertension.
5. Weintraub M, Hasday JD, Mushlin AI, et al.: A double-blind clinical trial in weight control: Use of fenfluramine and phentermine alone and in combination. Arch Intern Med 1984, 144:1143-1148.
6. Connolly HM, Crary JL, McGoon MD, et al.: Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997, 337:581-588. This article is the first report of valvulopathy induced by appetite suppressants. The authors describe the pathology and echocardiographic features of affected patients.
7. US Food and Drug Administration Center for Drug Evaluation and Research, and Center for Disease Control and Prevention. Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine. MMWR Morb Mortal Wkly Rep 1997, 46:1061-1066.
8. Klein AL, Burstow DJ, Tajik AJ, et al.: Age-related prevalence of valvular regurgitation in normal subjects: A comprehensive color flow examination of 118 volunteers. J Am Soc Echocardiogr 1990, 3:54-63.
9. Khan MA, Herzog CA, St. Peter JV, et al.: The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressants drugs. N Engl J Med 1998, 339:713-718.
10. Weissman NJ, Tighe J, Gottdiener J, et al.: An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine or placebo. N Engl J Med 1998, 339:725-732.
11. Kancherla MK, Salti HI, Mulderink TA, et al.: Echocardiographic prevalence of mitral and/or aortic regurgitation in patients exposed to either fenfluraminephentermine combination or to dexfenfluramine. Am J Cardiol 1999, 84:1335-1338.
12. Teramae CY, Connolly HM, Grogan M, et al.: Diet drug-related cardiac valve disease: The Mayo Clinic echocardiographic laboratory experience. Mayo Clin Proc 2000, 75:456-461.
13. Lepor NE, Gross SB, Daley WL, et al.: Dose and duration of fenfluraminephentermine therapy impacts the risk of significant valvular heart disease. Am J Cardiol 2000, 86:107-110.
14. Gardin JM, Schumacher D, Constantine G, et al.: Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phenterminefenfluramine. JAMA 2000, 283(13):1703-1709. This study is a multicenter study of the prevalence of valve disease related to appetite suppressants compared with placebo and establishes that the prevalence of aortic regurgitation only is increased, whereas the prevalence of mitral regurgitation is not different compared with placebo.
15. Shively BK, Roldan CA, Gill EA, et al.: Prevalence and determinants of valvulopathy in patients treated with dexfenfluramine. Circulation 1999, 100:2161-2167.
16. Burger AJ, Sherman HB, Charlamb MJ, et al.: Low prevalence of valvular heart disease in 226 phentermine-fenfluramine protocol subjects prospectively followed for up to 30 months. J Am Coll Cardiol 1999, 34:1153-1158. This study compared the prevalence of valvulopathy induced by appetite suppressants compared with a sample of normal population from Framingham heart study.
17. Jick H, Vasilakis C, Weinrauch L, et al.: A population-based study of appetite suppressant drugs and the risk of cardiac-valve regurgitation. N Engl J Med 1998, 339:719-724.
18. Biswas SS, Donovan CL, Forbess JM, et al.: Valve replacement for appetite suppressant-induced valvular heart disease. Ann Thorac Surg 1999, 67:1819-1822.
19. Caccitolo JA, Connolly HM, Rubenson DS, et al.: Operation for fenfluraminephentermine associated valvular heart disease [abstract]. Circulation 1998, 98(suppl 1):1-832.
20. Mast ST, Jollis JG, Ryan T, et al.: The progression of fenfluramine-associated valvular heart disease assessed by echocardiography. Ann Intern Med 2001, 134:261-266. This study is one of the first to show the natural history and progression of valvulopathy induced by appetite suppressants.
21. Weissman NJ, Panza JA, Tighe JF, et al.: Natural history of valvular regurgitation 1 year after discontinuation of dexfenfluramine therapy. Ann Intern Med 2001, 134:267-273. This study on the natural history of valve disease related to appetite suppressants has the merit to show the data after 1 year of follow-up evaluation.
22. Hensrud DD, Connolly HM, Grogan M, et al.: Echocardiographic improvement over time after cessation of use of fenfluramine and phentermine. Mayo Clin Proc 1999, 74:1191-1197.
23. 2B receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol 2000, 57:75-81.
24. Robolio PA, Rigolin VH, Wilson JS, et al.: Carcinoid heart disease: Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography. Circulation 1995, 92:790-795.
25. Pellika PA, Tajik AJ, Khandheria BK, et al.: Carcinoid heart disease: Clinical and echocardiographic spectrum in 74 patients. Circulation 1993, 87:1188-1196.
26. Redfield AJ, Nicholson WJ, Edwards WD, et al.: Valve disease associated with ergot alkaloid use: Echocardiographic and pathologic correlations. Ann Intern Med 1992, 117:50-52.
27. Benot F, Herve P, Petitpretz P, et al.: Primary pulmonary hypertension and fenfluramine use. Br Heart J 1993, 70:537-541.
28. Thomas SH, Butt AY, Corris PA, et al.: Appetite suppressants and primary pulmonary hypertension in the United Kingdom. Br Heart J 1995, 74:660-663.
29. Weyman AE: Obesity is significantly correlated with pulmonary artery systolic pressure [abstract]. Int J Obesity 2000, 24(suppl 1):629.
30. Fishman AP: Aminorex to fen-phen: An epidemic foretold. Circulation 1999, 99:156-161.
31. Bonow R, Carabello B, de Leon AC, et al.: ACC/AHA guidelines for the management of patients with valvular heart disease. J Am Coll Cardiol 1998, 32:1486-1588.